Ian M Thompson is affiliated with the University of Texas Health Science Center.
Dr. Thompson is the director of the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio.He serves as a trustee of the American Board of Urology, and as chairman of the Early Detection Research Network of the National Cancer Institute.He also is chairman of the Genitourinary Cancer Committee of the Southwest Oncology Group, one of the largest cancer treatment trials organizations in the world.He was the principal investigator of the Prostate Cancer Prevention Trial, an 18,882-subject study published in 2003 that demonstrated that the drug finasteride can reduce the risk of prostate cancer.He returned to San Antonio first as a faculty urologist at Brooke Army Medical Center, then as chief of urology, and completed his military career as chairman of the department of surgery at BAMC.He retired from UT Health in December and became president of CHRISTUS Santa Rosa Hospital Medical Center and vice president of their market oncology service line in January.
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
University of Texas Health Science Center
Ian Thompson, MD, SWOG principal investigator of the Prostate Cancer Prevention Trial. Finasteride, a generic hormone-blocking drug, was found to reduce the risk of prostate cancer by 25 percent in the landmark Prostate Cancer Prevention Trial . "Finasteride is safe, inexpensive, and effective as a preventive strategy for prostate cancer," said Ian Thompson, Jr, MD, principal investigator of the PCPT for SWOG. Along with SWOG biostatisticians Catherine Tangen, DrPH, and Phyllis Goodman, MS, of Fred Hutchinson Cancer Research Center, Thompson sought to determine whether the increased number of high-grade cancers detected through the PCPT years ago would result in more prostate cancer deaths over time.